| |
You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online during the Annual Meeting, you may vote your shares by proxy in advance of the Annual Meeting via the internet, by telephone or, if you receive a paper proxy card in the mail, by mailing the completed proxy card. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card.
|
| |
| |
Even if you have voted by proxy, you may still vote online during the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote during the Annual Meeting, you must follow the instructions from such organization and will need to obtain a proxy issued in your name from that record holder.
|
| |
| | |
Page
|
| |||
| | | | 2 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 14 | | | |
| | | | 23 | | | |
| | | | 25 | | | |
| | | | 26 | | | |
| | | | 27 | | | |
| | | | 49 | | | |
| | | | 52 | | | |
| | | | 55 | | | |
| | | | 56 | | | |
| | | | 57 | | |
Name
|
| |
Age
|
| |
Principal Occupation/ Position
|
|
Class III director nominees for election
at the 2022 Annual Meeting of Stockholders |
| ||||||
Fred E. Cohen, M.D., D.Phil. | | |
65
|
| | Director | |
Norman Payson, M.D. | | |
73
|
| | Director | |
Beth Seidenberg, M.D. | | |
65
|
| | Lead Independent Director | |
Class I directors continuing in office
until the 2023 Annual Meeting of Stockholders |
| ||||||
Malissia Clinton* | | |
53
|
| | Director | |
Kevin Gordon | | |
59
|
| | Director | |
Cheryl Scott | | |
72
|
| | Director | |
Class II directors continuing in office
ntil the 2024 Annual Meeting of Stockholders |
| ||||||
Peter Anevski | | |
54
|
| | Chief Executive Officer and Director | |
Roger Holstein | | |
70
|
| | Director | |
Jeff Park | | |
50
|
| | Director | |
David Schlanger | | |
62
|
| | Executive Chairman | |
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Corporate Governance |
| |||||||||
Malissia Clinton**
|
| | | | | | | | | | | | | | | | X | | |
Fred Cohen, M.D., D.Phil.
|
| | | | | | | | | | X* | | | | | | | | |
Kevin Gordon
|
| | | | X | | | | | | | | | | | | X | | |
Roger Holstein
|
| | | | | | | | | | X | | | | | | | | |
Jeff Park
|
| | | | X* | | | | | | X | | | | | | | | |
Norman Payson, M.D.
|
| | | | X | | | | | | | | | | | | X* | | |
Cheryl Scott
|
| | | | | | | | | | | | | | | | X | | |
Beth Seidenberg, M.D.
|
| | | | | | | | | | X | | | | | | | | |
| |
Board Diversity Matrix (As of April 14, 2022)
|
| | ||||||||||||||||
| |
Total Number of Directors
|
| | |
10
|
| | ||||||||||||
| | | | | |
Female
|
| | |
Male
|
| | |
Non-Binary
|
| | |
Did Not Disclose
Gender |
| |
| |
Part I: Gender Identity
|
| | ||||||||||||||||
| |
Directors
|
| | |
3
|
| | |
7
|
| | |
—
|
| | |
0
|
| |
| |
Part II: Demographic Background
|
| | ||||||||||||||||
| |
African American or Black
|
| | |
1
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
Alaskan Native or Native American
|
| | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
Asian
|
| | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
Hispanic or Latinx
|
| | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
Native Hawaiian or Pacific Islander
|
| | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
White
|
| | |
2
|
| | |
7
|
| | |
—
|
| | |
—
|
| |
| |
Two or More Races or Ethnicities
|
| | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| |
LGBTQ+
|
| | |
1
|
| | ||||||||||||
| |
Did Not Disclose Demographic Background
|
| | |
0
|
| |
| | |
Fiscal Year Ended
|
| |||
| | |
2021
|
| |
2020
|
|
| | |
(in thousands)
|
| |||
Audit Fees(1)
|
| |
$700
|
| |
$775
|
|
Audit-related Fees(2)
|
| |
—
|
| |
—
|
|
Tax Fees(3)
|
| |
119
|
| |
112
|
|
All Other Fees(4)
|
| |
—
|
| |
4
|
|
Total Fees
|
| |
$819
|
| |
$891
|
|
Name
|
| |
Age
|
| |
Principal Position
|
| |||
David Schlanger
|
| | | | 62 | | | | Executive Chairman | |
Peter Anevski
|
| | | | 54 | | | | Chief Executive Officer and Director | |
Jennifer Bealer
|
| | | | 41 | | | |
Executive Vice President, General Counsel and Secretary
|
|
Mark Livingston
|
| | | | 56 | | | | Chief Financial Officer | |
Michael Sturmer
|
| | | | 45 | | | | President | |
|
What We Do
|
| |
What We Don’t Do
|
|
|
✓
Deliver a significant portion of executive compensation through long-term equity to align interests with stockholders
|
| |
X
No pledging or hedging of Progyny stock
|
|
|
✓
Engage an independent compensation consultant
|
| |
X
No excessive perquisites
|
|
|
✓
Benchmark certain pay against industry peers to offer market-competitive compensation
|
| |
X
No supplemental executive retirement plans
|
|
|
✓
Set challenging company metrics and targets
|
| |
X
No compensation-related tax gross-ups
|
|
|
✓
Conduct an annual executive compensation review
|
| |
X
No incentives that encourage excessive risk- taking
|
|
| Apollo Medical Holding Inc. | | | Healthstream Inc. | |
| Benefitfocus, Inc. | | | HMS Holdings Corp | |
| Care.com, Inc. | | | National Research Corp | |
| Castlight Health Inc. | | | NextGen Healthcare Inc. | |
| Corvel Corp | | | Tabula Rasa Healthcare Inc. | |
| Digirad Corp | | | Teladoc Health Inc. | |
| Evolent Health Inc. | | | Tivity Health Inc. | |
| HeathEquity Inc. | | | Wageworks, Inc. | |
Named Executive Officer
|
| |
Fiscal 2021 Base
Salary |
| |||
David Schlanger
|
| | | $ | 500,000 | | |
Peter Anevski
|
| | | $ | 425,000 | | |
Mark Livingston
|
| | | $ | 425,000 | | |
Jennifer Bealer
|
| | | $ | 300,000 | | |
Lisa Greenbaum
|
| | | $ | 113,751(1) | | |
Named Executive Officer
|
| |
Target Percentage
Salary |
| |||
David Schlanger
|
| | | | 75% | | |
Peter Anevski
|
| | | | 75% | | |
Mark Livingston
|
| | | | 60% | | |
Jennifer Bealer
|
| | | | 40% | | |
Lisa Greenbaum(1)
|
| | | | N/A | | |
|
Performance Metric/Goal
|
| |
Actual
|
| |
Assessment
|
|
|
Sales and Account Management – grow client base, upsells to existing clients and client retention
|
| |
Despite disruption due to COVID-19, entered 2022 with a large contractual backlog of estimated annual revenues
|
| |
Exceeds expectations
|
|
|
Clinical Outcomes and Scientific Leadership – generate industry leading clinical outcomes that exceed national averages
|
| |
All clinical outcomes substantially exceeded most recently reported national averages and are industry leading
|
| |
Exceeds expectations
|
|
|
Member Services – continue to improve and refine the member experience to maintain competitive differentiation
|
| |
NPS score of 81+ by year-end and average member satisfaction survey score of 4.9 out of 5
|
| |
Exceeds expectations
|
|
|
Provider Network and Relations – continue to have a high quality network and maintain unique collaborative relationship with network providers
|
| |
Continued to grow network and created clinic watch lists to ensure alignment with high standards
|
| |
Meets expectations
|
|
|
Performance Metric/Goal
|
| |
Actual
|
| |
Assessment
|
|
|
Organization – maintain the unique mission-driven and collaborative culture
|
| |
Positive results from employee engagement survey and low attrition
|
| |
Exceeds expectations
|
|
|
Strategic – determine priority areas for growth
|
| |
Determined priority areas for board’s consideration, including male infertility services, PGNY among fastest ever from IPO to S&P400
|
| |
Exceeds expectations
|
|
Name
|
| |
Target
|
| |
Overall Assessment
|
| |
Actual Bonus Payout
|
| ||||||
David Schlanger
|
| | | $ | 375,000 | | | |
Meets expectations
|
| | | $ | 350,000 | | |
Peter Anevski
|
| | | $ | 318,750 | | | |
Exceeds expectations
|
| | | $ | 350,000 | | |
Mark Livingston
|
| | | $ | 255,000 | | | |
Meets expectations
|
| | | $ | 255,000 | | |
Jennifer Bealer
|
| | | $ | 120,000 | | | |
Exceeds expectations
|
| | | $ | 150,000 | | |
Lisa Greenbaum
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
|
Named Executive Officer
|
| |
2021 Stock Options
Granted |
| |
2021 RSUs Granted
|
| ||||||
Mark Livingston
|
| | | | 270,000 | | | | | | 82,000 | | |
Jennifer Bealer
|
| | | | 135,000 | | | | | | 37,000 | | |
Lisa Greenbaum
|
| | | | 20,000 | | | | | | 7,000 | | |
Name and Principal Position during 2021
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)(1)
|
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total ($)
|
| ||||||||||||||||||||||||
David Schlanger
Chief Executive Officer |
| | | | 2021 | | | | | | 500,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,462 | | | | | | 862,462 | | |
| | | | | 2020 | | | | | | 500,000 | | | | | | 125,000 | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,312 | | | | | | 987,312 | | |
| | | | | 2019 | | | | | | 431,250 | | | | | | — | | | | | | — | | | | | | 4,240,075 | | | | | | 250,000 | | | | | | 42,871 | | | | | | 4,964,196 | | |
Peter Anevski President and Chief
Operating Officer |
| | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 10,770 | | | | | | 785,770 | | |
| | | | | 2020 | | | | | | 425,000 | | | | | | 156,250 | | | | | | — | | | | | | — | | | | | | 318,750 | | | | | | 9,861 | | | | | | 909,861 | | |
| | | | | 2019 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,251,665 | | |
Mark Livingston
Chief Financial Officer |
| | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | 4,521,210 | | | | | | 7,586,995 | | | | | | 255,000 | | | | | | 275,467 | | | | | | 13,063,672 | | |
| | | | | 2020 | | | | | | 389,776 | | | | | | 127,812 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 207,188 | | | | | | 132,230 | | | | | | 1,251,295 | | |
Jennifer Bealer
Executive Vice President and General Counsel |
| | | | 2021 | | | | | | 300,000 | | | | | | — | | | | | | 2,299,260 | | | | | | 4,309,487 | | | | | | 150,000 | | | | | | 10,170 | | | | | | 7,068,917 | | |
| | | | | 2020 | | | | | | 300,000 | | | | | | 70,000 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 120,000 | | | | | | 9,120 | | | | | | 893,409 | | |
Lisa Greenbaum(5)
Executive Vice President and Chief Client Officer |
| | | | 2021 | | | | | | 113,751 | | | | | | — | | | | | | 299,460 | | | | | | 438,920 | | | | | | — | | | | | | 26,054 | | | | | | 878,185 | | |
| | | | | 2020 | | | | | | 325,000 | | | | | | 75,000 | | | | | | 81,060 | | | | | | 94,529 | | | | | | 225,000 | | | | | | 56,574 | | | | | | 857,163 | | |
Name
|
| |
Grant Date
|
| |
Threshold ($)
|
| |
Target ($)
|
| |
Maximum ($)
|
| |
All Other
Stock Awards: Number of Shares of Stock or Units (#) |
| |
All Other
Option Awards: Number of Securities Underlying Options (#) |
| |
Exercise or
Base Price of Option Awards ($/Sh) |
| |
Grant Date
Fair Value of Stock and Option Awards($)(1) |
| ||||||||||||||||||||||||
David Schlanger
|
| | | | N/A | | | | | | — | | | | | | 375,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Peter Anevski
|
| | | | N/A | | | | | | — | | | | | | 318,750(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Livingston
|
| | | | N/A | | | | | | — | | | | | | 255,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000 | | | | | | — | | | | | | — | | | | | | 4,221,750 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 250,000 | | | | | | 56.29 | | | | | | 7,148,075 | | | ||
Jennifer Bealer
|
| | | | N/A | | | | | | — | | | | | | 120,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000 | | | | | | — | | | | | | — | | | | | | 1,999,800 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 115,000 | | | | | | 66.66 | | | | | | 3,870,567 | | | ||
Lisa Greenbaum
|
| | | | N/A | | | | | | — | | | | | | 325,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | |
| | | | | | | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Grant Date
|
| |
Number of
Securities Underlying Unexercised Options (#)Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market Value
of Shares or Units of Stock That Have Not Vested ($)(1) |
| |||||||||||||||||||||
David Schlanger
|
| | | | 5/24/2019 | | | | | | 1,207,723(2) | | | | | | 662,299(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 8/17/2018 | | | | | | 202,794(3) | | | | | | — | | | | | | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | |
| | | | | 8/4/2017 | | | | | | 2,234,385(3) | | | | | | — | | | | | | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | |
Peter Anevski
|
| | | | 5/24/2019 | | | | | | 1,017,774(2) | | | | | | 603,862(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 8/17/2018 | | | | | | 34,042(3) | | | | | | — | | | | | | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | |
| | | | | 8/4/2017 | | | | | | 472,107(3) | | | | | | — | | | | | | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | |
Mark Livingston
|
| | | | 9/01/2021 | | | | | | — | | | | | | 250,000(4) | | | | | | 56.2900 | | | | | | 08/31/2031 | | | | | | — | | | | | | — | | |
| | | | | 9/01/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000(4) | | | | | | 3,776,250 | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | 20,000(5) | | | | | | 42.7800 | | | | | | 03/02/2031 | | | | | | — | | | | | | — | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000(5) | | | | | | 352,450 | | |
| | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000(6) | | | | | | 251,750 | | |
| | | | | 3/9/2020 | | | | | | 1,126(7) | | | | | | 5,060(7) | | | | | | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | |
| | | | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,967(7) | | | | | | 99,038 | | |
| | | | | 6/4/2019 | | | | | | 13,750(8) | | | | | | 116,877(8) | | | | | | 3.9545 | | | | | | 6/3/2029 | | | | | | — | | | | | | — | | |
Jennifer Bealer
|
| | | | 11/08/2021 | | | | | | — | | | | | | 115,000(9) | | | | | | 66.6600 | | | | | | 11/07/2031 | | | | | | — | | | | | | — | | |
| | | | | 11/08/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000(9) | | | | | | 1,510,500 | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | 20,000(5) | | | | | | 42.7800 | | | | | | 03/02/2031 | | | | | | — | | | | | | — | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000(5) | | | | | | 352,450 | | |
| | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000(6) | | | | | | 251,750 | | |
| | | | | 3/9/2020 | | | | | | 563(7) | | | | | | 5,060(7) | | | | | | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | |
| | | | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,967(7) | | | | | | 99,038 | | |
| | | | | 5/24/2019 | | | | | | 6,875(2) | | | | | | 54,438(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 5/22/2019 | | | | | | 1,265(2) | | | | | | 9,488(2) | | | | | | 3.9545 | | | | | | 5/21/2029 | | | | | | — | | | | | | — | | |
Lisa Greenbaum(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of Shares
Acquired on Exercise (#)(1) |
| |
Value Realized on
Exercise ($)(7) |
| |
Number of Shares
Acquired on Vesting (#)(1) |
| |
Value Realized on
Vesting ($)(8) |
| ||||||||||||
David Schlanger
|
| | | | 1,500,000 | | | | | | 79,489,166 | | | | | | — | | | | | | — | | |
Peter Anevski
|
| | | | 403,538 | | | | | | 23,140,575 | | | | | | — | | | | | | — | | |
Mark Livingston
|
| | | | 78,439(2) | | | | | | 4,689,959 | | | | | | 4,033(3) | | | | | | 212,696 | | |
Jennifer Bealer
|
| | | | 71,579(4) | | | | | | 3,658,585 | | | | | | 4,033 | | | | | | 212,696 | | |
Lisa Greenbaum
|
| | | | 57,668(5) | | | | | | 2,829,553 | | | | | | 876(6) | | | | | | 36,941 | | |
Name
|
| |
Benefit
|
| |
Termination Without Cause or
for Good Reason / Cause (no Change in Control) ($) |
| |
Termination Without Cause or
for Good Reason / Cause in Connection with a Change in Control ($)(7) |
| ||||||
David Schlanger | | | Cash | | | | | 850,000(1) | | | | | | 850,000(1) | | |
| | | Equity Acceleration | | | | | 21,690,175(3) | | | | | | 30,727,693(4) | | |
| | |
All Other Payments or Benefits
|
| | | | 28,723(5) | | | | | | 28,723(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 22,568,898 | | | | | | 31,606,416 | | |
Peter Anevski | | | Cash | | | | | 775,000(1) | | | | | | 775,000(1) | | |
| | | Equity Acceleration | | | | | 19,776,314(3) | | | | | | 28,016,479(4) | | |
| | |
All Other Payments or Benefits
|
| | | | 42,107(5) | | | | | | 42,107(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 20,593,421 | | | | | | 28,833,586 | | |
Mark Livingston | | | Cash | | | | | 467,500(2) | | | | | | 467,500(2) | | |
| | | Equity Acceleration | | | | | 2,186,996(3) | | | | | | 10,191,037(4) | | |
| | |
All Other Payments or Benefits
|
| | | | 31,228(5) | | | | | | 31,228(5) | | |
| | | Total | | | | | 2,685,724 | | | | | | 10,689,765 | | |
Jennifer Bealer(6) | | | Cash | | | | | — | | | | | | — | | |
| | | Equity Acceleration | | | | | — | | | | | | — | | |
| | |
All Other Payments or Benefits
|
| | | | — | | | | | | — | | |
| | | Total | | | | | — | | | | | | — | | |
Plan Category
|
| |
Number of Shares to
be issued upon exercise of outstanding options, warrants and rights (#) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights ($) |
| |
Number of Shares
remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) (#) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 17,254,882(1) | | | | | $ | 24.25 | | | | | | 5,721,311(2) | | |
Equity compensation plan not approved by security
holders |
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 17,254,882 | | | | | $ | 24.25 | | | | | | 5,721,311 | | |
Position
|
| |
Annual Retainer
|
| |||
Board of Directors
|
| | | $ | 40,000 | | |
Board of Directors Independent Chair or Lead Independent Director
|
| | | $ | 25,000 | | |
Audit Committee Chair
|
| | | $ | 20,000 | | |
Compensation Committee Chair
|
| | | $ | 10,000 | | |
Nominating and Corporate Governance Committee Chair
|
| | | $ | 7,500 | | |
Position
|
| |
Initial Grant
|
| |||
Board of Directors
|
| | | | 44,000 | | |
Board of Directors Independent Chair or Lead Independent Director
|
| | | | 8,800 | | |
Audit Committee Chair
|
| | | | 6,600 | | |
Compensation Committee Chair
|
| | | | 4,400 | | |
Nominating and Corporate Governance Committee Chair
|
| | | | 2,200 | | |
Position
|
| |
Annual Committee
Grant (Options) |
| |
Annual Committee
Grant (RSUs) |
| ||||||
Board of Directors
|
| | | $ | 338,587 | | | | | $ | 139,750 | | |
Board of Directors Independent Chair or Lead Independent Director
|
| | | $ | 54,174 | | | | | $ | 55,900 | | |
Audit Committee Chair
|
| | | $ | 40,631 | | | | | $ | 27,950 | | |
Compensation Committee Chair
|
| | | $ | 27,101 | | | | | $ | 27,950 | | |
Nominating and Corporate Governance Committee Chair
|
| | | $ | 13,544 | | | | | $ | 27,950 | | |
Name(5)
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Stock Awards
($)(1) |
| |
Option Awards
($)(1) |
| |
Total ($)
|
| ||||||||||||
Beth Seidenberg, M.D.
|
| | | $ | 66,172(2) | | | | | $ | 195,572 | | | | | $ | 430,925 | | | | | $ | 692,669 | | |
Malissia Clinton
|
| | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Fred Cohen, M.D., D.Phil.
|
| | | $ | 50,000(3) | | | | | $ | 167,633 | | | | | $ | 401,222 | | | | | $ | 618,855 | | |
Kevin Gordon
|
| | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Roger Holstein
|
| | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Jeff Park
|
| | | $ | 61,079(4) | | | | | $ | 167,633 | | | | | $ | 416,074 | | | | | $ | 644,786 | | |
Norman Payson, M.D.
|
| | | $ | 47,500 | | | | | $ | 167,633 | | | | | $ | 386,345 | | | | | $ | 601,478 | | |
Cheryl Scott
|
| | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Name
|
| |
Options Outstanding
at Fiscal Year End (Exercisable) |
| |
Options Outstanding
at Fiscal Year End (Unexercisable) |
| |
Restricted Stock
Units Outstanding at Fiscal Year End(1) |
| |||||||||
Beth Seidenberg, M.D.
|
| | | | 66,800 | | | | | | 39,615 | | | | | | 3,094 | | |
Malissia Clinton
|
| | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Fred Cohen, M.D., D. Phil.
|
| | | | 59,096 | | | | | | 33,981 | | | | | | 2,652 | | |
Kevin Gordon
|
| | | | 48,833 | | | | | | 34,825 | | | | | | 2,210 | | |
Roger Holstein
|
| | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Jeff Park
|
| | | | 62,863 | | | | | | 39,180 | | | | | | 2,652 | | |
Norman Payson
|
| | | | 95,225 | | | | | | 35,043 | | | | | | 2,652 | | |
Cheryl Scott
|
| | | | 48,834 | | | | | | 34,824 | | | | | | 2,210 | | |
| | |
Beneficial Ownership(1)
|
| |||||||||
Beneficial Owner
|
| |
Number of
Shares |
| |
Percent of
Total |
| ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2)
|
| | | | 10,565,351 | | | | | | 11.4% | | |
BlackRock(3) | | | | | 7,923,625 | | | | | | 8.6% | | |
Macquarie Group Limited(4)
|
| | | | 7,471,794 | | | | | | 8.1% | | |
The Vanguard Group(5)
|
| | | | 6,475,504 | | | | | | 7.1% | | |
KPCB Holdings, Inc., as nominee(6)
|
| | | | 6,473,515 | | | | | | 7.1% | | |
Alger Associates, Inc.(7)
|
| | | | 4,560,319 | | | | | | 5.0% | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(8)
|
| | | | 1,992,592 | | | | | | 2.1% | | |
Jennifer Bealer(9)
|
| | | | 75,788 | | | | | | * | | |
Malissia Clinton(10)
|
| | | | 16,500 | | | | | | * | | |
Fred E. Cohen, M.D. D. Phil.(11)
|
| | | | 70,137 | | | | | | * | | |
Kevin Gordon(12)
|
| | | | 58,416 | | | | | | * | | |
Lisa Greenbaum(13)
|
| | | | 2,112 | | | | | | * | | |
Roger Holstein(14)
|
| | | | 16,500 | | | | | | * | | |
Mark Livingston(15)
|
| | | | 51,875 | | | | | | * | | |
Jeff Park(16)
|
| | | | 73,446 | | | | | | * | | |
Norman Payson, M.D.(17)
|
| | | | 759,984 | | | | | | * | | |
David Schlanger(18)
|
| | | | 3,488,992 | | | | | | 3.7% | | |
Beth Seidenberg, M.D.(19)
|
| | | | 6,780,721 | | | | | | 7.4% | | |
Cheryl Scott(20)
|
| | | | 56,417 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(21)
|
| | | | 13,678,790 | | | | | | 14.0% | | |
| | | | By Order of the Board of Directors | |
| | | |
/s/ Jennifer Bealer
Jennifer Bealer
|
|
| | | | Executive Vice President, General Counsel and Secretary | |